DNA clues could forecast blood cancer progression years before diagnosis
A small study of 30 patients with myeloproliferative neoplasms found that new DNA changes in blood cells often appeared years before routine tests showed progression, with stable disease showing little genetic change and cases advancing toward myeloid leukemia. Some participants developed AML, while others remained stable; patterns were also linked to common treatments (hydroxyurea and azacitidine) but did not prove causation. The findings are associative and limited by size, yet suggest that serial DNA monitoring could enable earlier, more personalized monitoring and potentially guide future targeted interventions.
